Complex pharmacokinetic (PK) properties including nonlinear elimination were encountered by some monoclonal antibodies (mAbs), and classic compartment models sometimes failed to appropriately describe those properties. In this work, a new model was built on a comprehensive analysis of the complex elimination of mAbs. This new model was firstly utilized to fit with the single-dose plasma concent...

The identification of numerous breast cancer antigens has generated increasing enthusiasm for the application of immune-based therapies in breast malignancies. Although the use of monoclonal antibodies has revolutionized the "targeted therapy" of breast cancer, and the immunomodulatory effects of bisphosphonates continue to be evaluated, few studies to date have demonstrated widespread utility ...

background: targeting of cd20 antigen with monoclonal antibodies has become the mainstay in the treatment of non-hodgkin's lymphomas and immunotherapeutic depletion of malignant b cells. accessibility of antigen is one of the crucial factors in development of monoclonal antibodies against this antigen. one major problem in expression of full length cd20 is aggregation and misfolding. there...

This is the first report of the production of monoclonal antibodies against elk coronavirus. The nucleoprotein gene of elk coronavirus was amplified by PCR and was cloned and expressed in a prokaryotic expression vector. Recombinant nucleocapsid protein was used to immunize mice for the production of hybridomas. Twelve hybridomas that produced monoclonal antibodies against the nucleocapsid prot...

the TCR-CD3 complex and peptide-presenting MHC products, which contribute to the interaction of APC and Tlymphocytes. Most notable are mAbs against CD4 and CD8 (1, 2), andlymphocyte function-associated antigen 1 (CDlla, LFA-1)t (3) and its ligand, intercellular adhesion molecule 1 (CD54, ICAM-1) (4). Each mAb inhibits antigen-driven T cell proliferation when antigen is presented by a variety of...

Last month, Part 1 of this discussion brief ly described the regulatory landscape for developing biosimilar therapeutic monoclonal antibodies (TMAbs). We identified certain specific structural components of TMAb drug substances that warrant particular attention because alterations to them are likely to affect therapeutic safety and effectiveness. Now we conclude by considering whether studies o...

The monoclonal antibodies can selectively target specific molecules, proteins or receptors in the body responsible for pathogenesis of a particular disorder. Some cytokines play key role in the development of proliferative diabetic retinopathy, neovascular age related macular degeneration, glaucoma and many other inflammatory conditions of eye. Monoclonal antibodies against VEGF and TNF-alpha s...

Aims: To measure the content of immunoreactive human pancreatic secretory trypsin inhibitor (irPSTI) in colonic carcinoma and adjacent normal colonic mucosa. Methods: From a stable hybridoma cell line producing monoclonal antibodies specific for human PSTI, a specific enzyme linked immunosorbent assay (ELISA) for human PSTI was developed. In a precipitation assay system these antibodies bound h...

(w ww .m ed kn ow .co m) . Monoclonal antibodies (MAbs), a new class of biological agents, are used these days in therapeutics and diagnosis. MAbs also labeled as ‘magic bullets’, are highly specific Department of Pharmacology, antibodies produced by a clone of single hybrid cells formed in the laboratory by fusion Christian Medical College and of B cell with the tumor cell. The hybridoma forme...

The breadth of repertoire yet beautiful specificity of the antibody response is the key to its physiological efficacy in vivo; it also underpins the attractiveness of antibodies as laboratory and clinical reagents. One aspect of the body's reaction to invasion by a microorganism is the activation and clonal expansion of antigen-reactive B lymphocytes. Once these have matured into plasma cells, ...